James Moy
Overview
Explore the profile of James Moy including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
22
Citations
430
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Dhingra S, Fu J, Cloherty G, Mallon P, Wasse H, Moy J, et al.
Front Immunol
. 2024 May;
15:1385858.
PMID: 38745674
Mechanisms underlying long COVID remain poorly understood. Patterns of immunological responses in individuals with long COVID may provide insight into clinical phenotypes. Here we aimed to identify these immunological patterns...
2.
Boler M, Anderson M, Rodgers M, Parumoottil J, Olivo A, Harris B, et al.
IJID Reg
. 2023 May;
7:277-280.
PMID: 37234563
Background: Commercial severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) antibody tests were developed before variants with spike protein mutations emerged, leading to concerns that these tests have reduced sensitivity for...
3.
Grimm L, Onyeukwu C, Kenny G, Parent D, Fu J, Dhingra S, et al.
Pathog Immun
. 2023 Mar;
7(2):143-170.
PMID: 36865568
Introduction: Neutralizing antibodies have been shown to develop rapidly following SARS-CoV-2 infection, specifically against spike (S) protein, where cytokine release and production is understood to drive the humoral immune response...
4.
Kuzel T, Fu J, Anderson M, Stec M, Boler M, Behun D, et al.
Vaccine
. 2022 Dec;
41(4):879-882.
PMID: 36572601
It has been demonstrated that after two doses, SARS-CoV-2 mRNA vaccine-induced neutralizing antibodies against Omicron subvariants are much lower than against wild type virus and a booster dose greatly increases...
5.
Anderson M, Stec M, Gosha A, Mohammad T, Boler M, Tojo Suarez R, et al.
J Infect Dis
. 2022 Oct;
226(11):1934-1942.
PMID: 36263799
Background: Long-term studies of vaccine recipients are necessary to understand severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) antibody durability and assess the impact of booster doses on antibody levels and...
6.
Holzmayer V, Anderson M, Ndembi N, Mbanya D, Moy J, Cloherty G
Biotechniques
. 2022 Oct;
73(4):193-203.
PMID: 36240056
Dried blood spots (DBSs) provide an alternative sample input for serologic testing. We evaluated DBSs for the ARCHITECT hepatitis B surface antigen (HBsAg) NEXT, hepatitis B e-antigen (HBeAg), anti-hepatitis B...
7.
Rodgers M, Olivo A, Harris B, Lark C, Luo X, Berg M, et al.
J Clin Virol
. 2022 Jan;
147:105080.
PMID: 35086043
Background: Viral diversity presents an ongoing challenge for diagnostic tests, which need to accurately detect all circulating variants. The Abbott Global Surveillance program monitors severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2)...
8.
Anderson M, Stec M, Rewane A, Landay A, Cloherty G, Moy J
JAMA Netw Open
. 2021 Aug;
4(8):e2119741.
PMID: 34357399
No abstract available.
9.
Anderson M, Holzmayer V, Vallari A, Taylor R, Moy J, Cloherty G
J Clin Virol
. 2021 Jun;
141:104855.
PMID: 34144453
Serologic testing for SARS-CoV-2 antibodies can be used to confirm diagnosis, estimate seroprevalence, screen convalescent plasma donors, and assess vaccine efficacy. Dried blood spot (DBS) samples have been used for...
10.
Clougherty J, Kinnee E, Cardet J, Mauger D, Bacharier L, Beigelman A, et al.
Lancet Respir Med
. 2021 Feb;
9(4):330-332.
PMID: 33539731
No abstract available.